In the News
October 10, 2023
Agenus subsidiary, SaponiQx, a leader in saponin-based adjuvant discovery and production, announces a pivotal advancement in vaccine research and production with the availability of cGMP (current good manufacturing practice) STIMULON™ cultured plant cell (cpc) QS-21.
April 28, 2023
Watch SaponiQx Presentation at Ginko Ferment Conference, 2023
Watch SaponiQx co-founder, President, and COO Chandresh Harjivan speak about the compelling mission of SaponiQx at the Ginkgo Ferment conference
April 27, 2023
Vaccines are widely acknowledged as the most life-saving medical innovation in history, helping extend human life expectancy from 35 to 75 years in a century. SaponiQx exists because we believe we can be part of a global solution, enabling the development of next-generation safe and effective vaccines while increasing accessibility.
March 1, 2023
SaponiQx’s QS-21 STIMULON™ is a key adjuvant component in GSK’s Shingrix and Arexvy vaccines, leading vaccines in the prevention of Shingles and RSV.
February 1, 2023
Through SaponiQx’s membership in the Medical CBRN Defense Consortium, we will be able to integrate our unparalleled saponin adjuvant expertise into the biodefense community.
September 10, 2021
SaponiQx is proud to partner with Ginkgo Bioworks, Inc. to develop the next generation of saponin adjuvants. Pairing SaponiQx’s unique expertise in saponins and Gingko Bioworks’ powerful Foundry technology will provide a platform for innovation, moving the vaccine and adjuvant fields forward.
